Antoun Ibrahim, Kotb Ahmed I, Vali Zakkariya, Abdelrazik Ahmed, Koev Ivelin, Safwan Kassem, Lau Edward Y M, Somani Riyaz, Ng Ghulam André
Department of Cardiovascular Sciences, Clinical Science Wing, University of Leicester, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK.
Department of Cardiology, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester LE3 9QP, UK.
J Cardiovasc Dev Dis. 2024 Nov 30;11(12):385. doi: 10.3390/jcdd11120385.
pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (PAF) improves health-related quality of life (QoL). This study compares QoL improvement after radiofrequency ablation (RF) and cryoballoon ablation (cryo) and assesses additional ablations' role in QoL improvement.
we evaluated the QoL of consecutive patients with first-time RF and cryo for PAF between January 2017 and June 2019. A combined EQ-VAS, AFEQT, and EQ-5D-3L paper questionnaire was sent to patients at baseline, 12, and 30 months after the procedure. Procedure and patient details were collected from medical notes.
the analysis included 207 patients, of which 127 (61%) had RF and 144 (70%) were males. RF patients had more additional ablations (52 [41%] versus 22 [28%], = 0.01). There was a significant improvement from baseline to 12 months post-RF in AFEQT (43 ± 9 to 83 ± 7.8, < 0.001), EQ-5D-3L (-0.01 ± 0.01 to 1.1 ± 0.02, < 0.001), and EQ-VAS (51 ± 8 to 77 ± 13, = 0.01). Similarly, an improvement at 12 months was observed after cryo in AFEQT (55 ± 11 to 77 ± 9, < 0.001), EQ-5D-3L (-0.04 ± 0.03 to 1.3 ± 0.03, < 0.001), and EQ-VAS (56 ± 7 to 85 ± 9, = 0.01). QoL improvement was similar between RF and cryo. Additional ablations provided no additional QoL improvement compared to patients with PVI alone.
Patients undergoing first-time PVI for PAF, RF, and cryo showed similar QoL improvement at 12 months, which was sustained at 30 months. Additional ablations did not provide further QoL benefits.
阵发性心房颤动(PAF)的肺静脉隔离(PVI)可改善健康相关生活质量(QoL)。本研究比较了射频消融(RF)和冷冻球囊消融(cryo)后QoL的改善情况,并评估了额外消融在改善QoL中的作用。
我们评估了2017年1月至2019年6月期间因PAF首次接受RF和cryo治疗的连续患者的QoL。在基线、术后12个月和30个月向患者发送了一份包含EQ-VAS、AFEQT和EQ-5D-3L的纸质问卷。从病历中收集手术和患者的详细信息。
分析纳入207例患者,其中127例(61%)接受RF治疗,144例(70%)为男性。接受RF治疗的患者有更多的额外消融(52例[41%]对22例[28%],P = 0.01)。从基线到RF术后12个月,AFEQT(43±9至83±7.8,P < 0.001)、EQ-5D-3L(-0.01±0.01至1.1±0.02,P < 0.001)和EQ-VAS(51±8至77±13,P = 0.01)均有显著改善。同样,cryo术后12个月,AFEQT(55±11至77±9,P < 0.001)、EQ-5D-3L(-0.04±0.03至1.3±0.03,P < 0.001)和EQ-VAS(56±7至85±9,P = 0.01)也有改善。RF和cryo术后QoL改善相似。与仅接受PVI的患者相比,额外消融并未带来额外的QoL改善。
首次因PAF接受PVI、RF和cryo治疗的患者在12个月时QoL改善相似,且在30个月时仍持续。额外消融并未带来进一步的QoL益处。